Alternatives to Iambic Therapeutics

Clinical-stage precision medicine company using protein motion insights for drug discovery.

Data-driven drug discovery and development company using machine learning and high-throughput biology.

AI-driven biotechnology company developing novel protein therapeutics through generative biology.

AI-powered website builder that creates professional websites in minutes from a simple description.

AI-powered platform for understanding disease biology and accelerating drug discovery.

AI-guided drug discovery platform for tissue-targeted medicines.

AI-powered biotechnology company developing RNA therapeutics for genetic diseases.

NewLimit is developing epigenetic therapies to extend human healthspan by reprogramming aging cells.

Caris Life Sciences is a leading innovator in molecular science, offering precision medicine solutions for cancer patients through advanced molecular profiling.

Guardant Health is a precision oncology company that develops and commercializes liquid biopsy tests for cancer detection, recurrence monitoring, and treatment selection.

A precision biotechnology company developing a blood-based platform for early cancer detection and treatment.

AI-driven drug discovery platform accelerating breakthrough scientific research.

Phenomics-driven AI company translating disease biology into precision medicine discoveries.

Biopharmaceutical company developing therapies for neurodegenerative diseases, focusing on crossing the blood-brain barrier.

Leveraging the adaptive immune system to diagnose and treat disease.

BioAge Labs is a biotechnology company focused on developing therapies to extend human healthspan and lifespan.

Cradle Bio B.V. is a Dutch, Swiss biotechnology company that develops software using machine learning for protein engineering. It was founded in 2021 and is base

A global oncology company developing and commercializing innovative cancer treatments.

AI-powered platform for real-time organ physiology to accelerate human-relevant drug discovery.